Barcelona-based biotech SpliceBio raises 50 million euros in a Series A financing

SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, announced a €50 million Series A financing - the largest Series A round for a Spanish biotech company.

The financing was co-led by UCB Ventures and existing shareholder Ysios Capital and joined by new investors New Enterprise Associates (NEA), Gilde Healthcare, Novartis Venture Fund, and existing shareholder Asabys Partners.

This round is a testament to the growing potential of the biotech hub in Barcelona-Catalonia. In 2021, health companies raised €238 million, the highest figure to date.

The financing will enable SpliceBio to build a pipeline of Protein Splicing gene therapy programs, while advancing the lead program in Stargardt disease to the clinic. Stargardt disease is the most common form of juvenile macular dystrophy affecting more than 80,000 people in US and EU.

Miquel Vila-Perelló, PhD, Co-Founder and Chief Executive Officer of SpliceBio, said: "We are very pleased to attract this outstanding syndicate of institutional and corporate investors which validates our approach to developing next generation gene therapies. I am excited to lead an exceptional team as we continue to build our platform and advance our pipeline of gene therapy programs into the clinic".

Source: SpliceBio